Posted by Michael Wonder on 03 May 2019
Cresemba now available in Canada for the treatment of invasive aspergillosis and invasive mucormycosis
2 May 2019 - AVIR Pharma is pleased to announce that Cresemba (isavuconazole, as isavuconazonium sulphate), an anti-fungal approved for the treatment of adult patients with invasive aspergillosis or with invasive mucormycosis, is now available in Canada.
Invasive aspergillosis and invasive mucormycosis are life-threatening fungal infections often occurring in patients with solid organ transplants, cancer and other immunocompromised patients.
In June 2017 AVIR Pharma Inc. and Basilea Pharmaceutica entered into a distribution and license agreement for Cresemba and Zevtera in Canada. Cresemba is the only azole anti-fungal currently indicated for the treatment of both invasive aspergillosis and invasive mucormycosis.
